MedicExchange (KC) 22-Aug-08
To Go To MedicExchange (KC)
Sorafenib and bevacizumab promising for solid tumors
Combination therapy with sorafenib and bevacizumab in patients with advanced solid tumors results in enhanced antitumor activity, particularly in those with epithelial ovarian cancer.
Senior investigator Dr. Elise C. Kohn told Reuters Health that her group "combined two newer molecularly targeted agents, sorafenib (Nexavar) and bevacizumab (Avastin), with intriguing results."
In the August 1st issue of the Journal of Clinical Oncology, Dr. Kohn of the National Cancer Institute, Bethesda, and colleagues point out that sorafenib inhibits Raf kinase and vascular endothelial growth factor (VEGF) receptor. The monoclonal antibody bevacizumab also targets VEGF. The investigators hypothesized that the pair would complement inhibition of VEGF signaling.
In a phase I trial, the researchers studied 39 patients with solid tumors including ovarian cancer, renal cancer, melanoma and sarcoma.
The patients started therapy with 200 mg of sorafenib twice daily and bevacizumab 5 mg/kg every other week, doses well below those used with single-agent therapy.
However, 29 of the patients (74 per cent) required reduction to sorafenib to 200 mg once daily. Hand-foot-syndrome and hypertension were among the problems encountered. All but one patient who remained in the study for six months required a dose reduction.
Partial responses lasting from four to more than 22 months were seen in six of the 13 patients with ovarian cancer. One of the three patients with renal cancer maintained a response for 14 months. Altogether, partial remission or disease stabilization for a median of six months was achieved by 22 (59 per cent) of 37 patients available for follow-up.
"Increased toxicity was seen compared to what would be expected for either agent alone," continued Dr. Kohn, "but we also observed clinical benefit, particularly in ovarian cancer patients, who experienced prolonged tumor shrinkage and stabilization."
"These results," she concluded, "although promising, must be tested in larger groups of patients to assess if there is any true benefit of the combination."
To view the original article Click Here
Disclaimer
Kidney Cancer Resource (KCR) is not influenced by sponsors. The information contained herein is not intended as a substitute for the advice of an appropriately qualified and licensed physician or other licensed health care provider. The information provided here is for educational and information purposes only. Early accurate Diagnosis (Dx.) saves lives. Please check with a physician if you suspect you are ill, never ignore Symptoms. To help your health care specialist make an accurate Diagnosis please keep notes of dates, times and details of your Symptoms. We are not offering medical advice nor do we consider links, individuals or articles accessed through this site to be offering medical advice.
E&OE - Errors & Omissions Excepted
As much of the information posted on this Web Site for peoples convenience is of a medical or technical nature, and may be a matter of life or death the E&OE is a Disclaimer showing that to the best of our ability information is accurate and correctly written or transcribed. Before acting on information on this site you are responsible for checking it with your relevant medical team. We can not be held responsible for any Errors & Omissions made; nor for information on links and articles provided in good faith.
